Besides, due to the fact that our samples were collected at baseline, a test kit based on the expression of CLDN4 might be developed in the future to assist physicians to identify NSCLC patients with high risk of recurrent MPE when they were treated initially. The gene discussed is CLDN4; the disease is non-small cell lung carcinoma.